Axsome Therapeutics announced a June 2026 launch of Auvelity for Alzheimer's disease agitation during a Jefferies fireside chat. The company's COO confirmed the launch will leverage existing infrastructure instead of requiring a new rollout. This expansion marks the fourth approved indication within the company's commercial portfolio.
Axsome is increasing peak sales guidance for Auvelity in major depressive disorder. This adjustment follows a strong current sales run rate. The company expanded its sales force to support growth in the depression market.
Axsome submitted a new drug application for AXS-12 to treat cataplexy in narcolepsy. Management expects an FDA acceptance decision on the application this year.